-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
▎WuXi AppTec Content Team Editor On March 28, 2022, Axsome Therapeutics announced that it has reached a definitive agreement with Jazz Pharmaceuticals to acquire Sunosi (solriamfetol)
.
Sunosi is a dual-acting dopamine and norepinephrine reuptake inhibitor (DNRI) that helps maintain excessive daytime sleepiness (EDS) in adults with narcolepsy or obstructive sleep apnea (OSA) awake state
.
Under the terms of the agreement, Axsome will receive the development and commercialization rights to Sunosi owned by Jazz, and Jazz will receive an upfront payment of $53 million, as well as royalties on Sunosi's U.
S.
net sales in current and future indications
.
Narcolepsy is a disabling neurological disorder in which patients cannot properly regulate the cycle of sleep and wakefulness, resulting in symptoms of drowsiness
.
These patients sleep excessively during the day, or have repeated uncontrolled sleep episodes during normal wakefulness, as well as sudden onset of muscle weakness (cataplexy)
.
Sleep paralysis, vivid dreams, and hallucinations also sometimes occur while sleeping or waking up
.
OSA is a common disorder in which the airway becomes blocked during sleep, leading to frequent apnea, usually accompanied by loud snoring at night
.
People with OSA often cannot sleep properly, leading to daytime sleepiness symptoms
.
Continuous positive airway pressure (CPAP) therapy is an effective treatment for OSA
.
However, not all patients can tolerate CPAP therapy, and even in patients who use CPAP therapy, 13%-65% of patients will continue to experience somnolence
.
Sunosi works through a dual mechanism to promote the patient's ability to stay awake
.
It can cause an increase in dopamine and norepinephrine levels, where dopamine can directly stimulate wakefulness-promoting neurons in the patient's brain, while norepinephrine may act on the ventrolateral preoptic nucleus (VLPO) of the hypothalamus to shut down sleep.
driving factor
.
Most other current drugs for drowsiness work by stimulating the release of dopamine, and because they can cause a surge in dopamine levels, giving patients a sense of euphoria, there is a risk of addiction
.
Sunosi, on the other hand, does not stimulate dopamine release, thereby reducing the risk of addiction in patients
.
Sunosi is the first DNRI approved for the treatment of EDS in adults with narcolepsy or OSA, the press release noted
.
Mr.
Bruce Cozadd, Chairman and Chief Executive Officer of Jazz, said: "By developing and launching Sunosi, the Jazz team has laid the groundwork for Axsome to continue to support populations who may benefit from this much-needed therapy
.
Jazz remains committed to developing innovative neurological treatments for patients.
Science and Oncology Therapeutics
.
” said Dr.
Herriot Tabuteau, CEO of Axsome: “Sunosi has demonstrated clinically meaningful efficacy, has a unique mechanism of action, and has received positive patient and physician feedback
.
Excited about the complementarity of the R&D pipeline
.
"Reference: [1] Jazz Pharmaceuticals Announces Agreement to Divest Sunosi® (solriamfetol) to Axsome Therapeutics.
Retrieved March 28, 2022, from https:// -to-divest-sunosi-solriamfetol-to-axsome-therapeutics-301511396.
html[2] Axsome Therapeutics to Acquire Sunosi® from Jazz Pharmaceuticals, Expanding Axsome's Leadership in Neuroscience.
Retrieved March 28, 2022, from https://finance.
yahoo.
com/news/axsome-therapeutics-acquire-sunosi-jazz-100000764.
htmlDisclaimer: WuXi AppTec content team focuses on introducing global biomedical health research progress
.
This article is for information exchange purposes only, and the opinions in this article do not represent WuXi Kangde's position does not mean that WuXi AppTec supports or opposes the views in the article
.
This article is not a treatment plan recommendation
.
If you need treatment plan guidance, please go to a regular hospital for treatment
.
.
Sunosi is a dual-acting dopamine and norepinephrine reuptake inhibitor (DNRI) that helps maintain excessive daytime sleepiness (EDS) in adults with narcolepsy or obstructive sleep apnea (OSA) awake state
.
Under the terms of the agreement, Axsome will receive the development and commercialization rights to Sunosi owned by Jazz, and Jazz will receive an upfront payment of $53 million, as well as royalties on Sunosi's U.
S.
net sales in current and future indications
.
Narcolepsy is a disabling neurological disorder in which patients cannot properly regulate the cycle of sleep and wakefulness, resulting in symptoms of drowsiness
.
These patients sleep excessively during the day, or have repeated uncontrolled sleep episodes during normal wakefulness, as well as sudden onset of muscle weakness (cataplexy)
.
Sleep paralysis, vivid dreams, and hallucinations also sometimes occur while sleeping or waking up
.
OSA is a common disorder in which the airway becomes blocked during sleep, leading to frequent apnea, usually accompanied by loud snoring at night
.
People with OSA often cannot sleep properly, leading to daytime sleepiness symptoms
.
Continuous positive airway pressure (CPAP) therapy is an effective treatment for OSA
.
However, not all patients can tolerate CPAP therapy, and even in patients who use CPAP therapy, 13%-65% of patients will continue to experience somnolence
.
Sunosi works through a dual mechanism to promote the patient's ability to stay awake
.
It can cause an increase in dopamine and norepinephrine levels, where dopamine can directly stimulate wakefulness-promoting neurons in the patient's brain, while norepinephrine may act on the ventrolateral preoptic nucleus (VLPO) of the hypothalamus to shut down sleep.
driving factor
.
Most other current drugs for drowsiness work by stimulating the release of dopamine, and because they can cause a surge in dopamine levels, giving patients a sense of euphoria, there is a risk of addiction
.
Sunosi, on the other hand, does not stimulate dopamine release, thereby reducing the risk of addiction in patients
.
Sunosi is the first DNRI approved for the treatment of EDS in adults with narcolepsy or OSA, the press release noted
.
Mr.
Bruce Cozadd, Chairman and Chief Executive Officer of Jazz, said: "By developing and launching Sunosi, the Jazz team has laid the groundwork for Axsome to continue to support populations who may benefit from this much-needed therapy
.
Jazz remains committed to developing innovative neurological treatments for patients.
Science and Oncology Therapeutics
.
” said Dr.
Herriot Tabuteau, CEO of Axsome: “Sunosi has demonstrated clinically meaningful efficacy, has a unique mechanism of action, and has received positive patient and physician feedback
.
Excited about the complementarity of the R&D pipeline
.
"Reference: [1] Jazz Pharmaceuticals Announces Agreement to Divest Sunosi® (solriamfetol) to Axsome Therapeutics.
Retrieved March 28, 2022, from https:// -to-divest-sunosi-solriamfetol-to-axsome-therapeutics-301511396.
html[2] Axsome Therapeutics to Acquire Sunosi® from Jazz Pharmaceuticals, Expanding Axsome's Leadership in Neuroscience.
Retrieved March 28, 2022, from https://finance.
yahoo.
com/news/axsome-therapeutics-acquire-sunosi-jazz-100000764.
htmlDisclaimer: WuXi AppTec content team focuses on introducing global biomedical health research progress
.
This article is for information exchange purposes only, and the opinions in this article do not represent WuXi Kangde's position does not mean that WuXi AppTec supports or opposes the views in the article
.
This article is not a treatment plan recommendation
.
If you need treatment plan guidance, please go to a regular hospital for treatment
.
